BLRX: On Track for 60% Formulary Placement
BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting...
206 Views
BLRX: On Track for 60% Formulary Placement
BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting...
150 Views
BLRX: First Quarter 2024 Results
BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting...
206 Views
Multiple shots on goal and multiple partners
BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with...
152 Views
No more insights